In stages 1-3, considered to be early-stage ... also called end-stage kidney disease, your life expectancy depends on your treatment. With dialysis, people live an average of 5-10 years.
Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage ... % for placebo. Treatment emergent ...